Ugolini Heather, Bryan Jennifer, Hennessy Meliessa, Kaufman Howard L, D'Angelo Sandra
Memorial Sloan Kettering Cancer Center.
Rutgers Cancer Institute of New Jersey.
Clin J Oncol Nurs. 2019 Feb 1;23(1):E1-E9. doi: 10.1188/19.CJON.E1-E9.
Metastatic Merkel cell carcinoma (mMCC) is a rare skin cancer with poor prognosis. Avelumab is the first approved treatment option for patients with mMCC. Immune checkpoint inhibitors, such as avelumab, are associated with unique toxicities that can be effectively addressed with prompt recognition and appropriate management.
This article discusses the use of avelumab for the treatment of mMCC and management of associated toxicities.
Literature on mMCC disease state and clinical trial data for avelumab were reviewed.
Avelumab has been investigated in patients with mMCC either following disease progression after one or more prior lines of chemotherapy or no prior systemic therapy. These patients experience clinically meaningful benefit. About 70% of patients receiving avelumab experience treatment-related adverse events. Given the limited benefit of chemotherapy, managing symptoms related to avelumab is key to administering this effective treatment to patients with mMCC.
转移性默克尔细胞癌（mMCC）是一种预后较差的罕见皮肤癌。阿维鲁单抗是首个被批准用于治疗mMCC患者的药物。免疫检查点抑制剂，如阿维鲁单抗，会产生独特的毒性，通过及时识别和适当管理可有效应对。
本文讨论阿维鲁单抗在治疗mMCC及相关毒性管理中的应用。
回顾了关于mMCC疾病状态的文献以及阿维鲁单抗的临床试验数据。
阿维鲁单抗已在接受过一种或多种先前化疗方案后疾病进展或未接受过先前全身治疗的mMCC患者中进行了研究。这些患者获得了具有临床意义的益处。约70%接受阿维鲁单抗治疗的患者会出现与治疗相关的不良事件。鉴于化疗的益处有限，管理与阿维鲁单抗相关的症状是对mMCC患者施用这种有效治疗的关键。
